[go: up one dir, main page]

IL141957A0 - 5ht1 receptor agonists and metoclopramide for the treatment of migraine - Google Patents

5ht1 receptor agonists and metoclopramide for the treatment of migraine

Info

Publication number
IL141957A0
IL141957A0 IL14195799A IL14195799A IL141957A0 IL 141957 A0 IL141957 A0 IL 141957A0 IL 14195799 A IL14195799 A IL 14195799A IL 14195799 A IL14195799 A IL 14195799A IL 141957 A0 IL141957 A0 IL 141957A0
Authority
IL
Israel
Prior art keywords
metoclopramide
migraine
treatment
receptor agonists
agonists
Prior art date
Application number
IL14195799A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL141957A0 publication Critical patent/IL141957A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IL14195799A 1998-10-30 1999-10-18 5ht1 receptor agonists and metoclopramide for the treatment of migraine IL141957A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10632898P 1998-10-30 1998-10-30
PCT/IB1999/001694 WO2000025778A1 (en) 1998-10-30 1999-10-18 5ht1 receptor agonists and metoclopramide for the treatment of migraine

Publications (1)

Publication Number Publication Date
IL141957A0 true IL141957A0 (en) 2002-03-10

Family

ID=22310818

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14195799A IL141957A0 (en) 1998-10-30 1999-10-18 5ht1 receptor agonists and metoclopramide for the treatment of migraine

Country Status (34)

Country Link
US (2) US6255334B1 (es)
EP (1) EP1126840A1 (es)
JP (1) JP2002528497A (es)
KR (1) KR20010089363A (es)
CN (1) CN1325304A (es)
AP (1) AP2001002129A0 (es)
AR (1) AR019246A1 (es)
AU (1) AU5994799A (es)
BG (1) BG105534A (es)
BR (1) BR9914901A (es)
CA (1) CA2348543A1 (es)
CO (1) CO4950530A1 (es)
CZ (1) CZ20011468A3 (es)
EA (1) EA200100284A1 (es)
EE (1) EE200100243A (es)
GT (1) GT199900189A (es)
HK (1) HK1040929A1 (es)
HR (1) HRP20010298A2 (es)
HU (1) HUP0104696A3 (es)
ID (1) ID28291A (es)
IL (1) IL141957A0 (es)
IS (1) IS5898A (es)
MA (1) MA26702A1 (es)
NO (1) NO20012013D0 (es)
OA (1) OA11669A (es)
PA (1) PA8484801A1 (es)
PE (1) PE20001284A1 (es)
PL (1) PL347541A1 (es)
SK (1) SK5522001A3 (es)
TN (1) TNSN99203A1 (es)
TR (1) TR200101174T2 (es)
TW (1) TW524692B (es)
WO (1) WO2000025778A1 (es)
ZA (1) ZA200103322B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US6737042B2 (en) * 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
CA2447519C (en) * 2001-05-24 2008-09-16 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
EP1446102A1 (en) 2001-11-21 2004-08-18 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
CA2483687A1 (en) 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
CN1717237A (zh) 2002-11-26 2006-01-04 艾利斯达分子传输公司 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
JP2007516149A (ja) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ, インコーポレイテッド 基板温度の均一性を制御する方法、および、内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
EP2246086A3 (en) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heating unit
KR20130136010A (ko) 2005-04-13 2013-12-11 네우렉슨 인코포레이티드 Nos 저해 활성을 갖는 치환된 인돌 화합물
JP5350219B2 (ja) * 2006-04-13 2013-11-27 ニューラクソン,インコーポレーテッド Nos阻害活性を有する1,5および3,6−置換インドール化合物
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
WO2009062319A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
EP2219449A4 (en) * 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
EP2220074A4 (en) * 2007-11-16 2012-01-04 Neuraxon Inc 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine
KR102852740B1 (ko) 2018-02-02 2025-08-29 알렉스자 파마스티칼즈, 인크. 전기적 응축 에어로졸 디바이스

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
KR20000022239A (ko) * 1996-07-11 2000-04-25 토마스 헤인 인돌 선택성 세로토닌 작용약을 함유한 내포 복합체
GB9709739D0 (en) 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation

Also Published As

Publication number Publication date
MA26702A1 (fr) 2004-12-20
KR20010089363A (ko) 2001-10-06
CO4950530A1 (es) 2000-09-01
NO20012013L (no) 2001-04-24
OA11669A (en) 2005-01-05
GT199900189A (es) 2001-04-21
CA2348543A1 (en) 2000-05-11
TNSN99203A1 (fr) 2005-11-10
SK5522001A3 (en) 2002-05-09
ZA200103322B (en) 2002-06-10
IS5898A (is) 2001-03-16
EA200100284A1 (ru) 2001-10-22
HUP0104696A2 (hu) 2002-05-29
AU5994799A (en) 2000-05-22
ID28291A (id) 2001-05-10
TR200101174T2 (tr) 2001-10-22
AP2001002129A0 (en) 2001-06-30
NO20012013D0 (no) 2001-04-24
EP1126840A1 (en) 2001-08-29
BG105534A (en) 2001-12-29
CZ20011468A3 (cs) 2002-04-17
PA8484801A1 (es) 2000-09-29
TW524692B (en) 2003-03-21
WO2000025778A1 (en) 2000-05-11
PL347541A1 (en) 2002-04-08
HK1040929A1 (zh) 2002-06-28
BR9914901A (pt) 2001-07-17
CN1325304A (zh) 2001-12-05
EE200100243A (et) 2002-12-16
US6255334B1 (en) 2001-07-03
HRP20010298A2 (en) 2002-06-30
PE20001284A1 (es) 2000-11-22
JP2002528497A (ja) 2002-09-03
HUP0104696A3 (en) 2003-05-28
AR019246A1 (es) 2001-12-26
US20010020036A1 (en) 2001-09-06

Similar Documents

Publication Publication Date Title
IL141957A0 (en) 5ht1 receptor agonists and metoclopramide for the treatment of migraine
PL348817A1 (en) Compositions and methods for the treatment of anorectal disorders
EP1379224A4 (en) GUANYLATE CYCLASE RECEPTOR AGONISTS FOR THE TREATMENT OF TISSUE INFLAMMATION AND CARCINOGENESIS
HUP0104496A3 (en) Compositions comprising 1,1,1,3,3-pentafluorobutane and use of said compositions
HUP0600780A2 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
IL126592A0 (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthritis and other mmp-mediated disorders
IL138129A (en) Composition for therapy of estrogen-associated disorders
HUP9900163A3 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
IL146697A0 (en) SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
SG83723A1 (en) Novel therapeutic agents that modulate 5ht receptors
ZA954984B (en) Compositions and methods for the treatment of tumors
HU9702039D0 (en) Estrogen agonist/antagonists treatment of atheroscerosis
IL143385A0 (en) 5ht1 antagonists for antidepressant therapy
NO984432D0 (no) FremgangsmÕte for behandling av migrenesmerte
ZA981781B (en) The use of levobupivacaine in treating migraine
IL143212A0 (en) Compositions and methods for the treatment of tumor
ITMI991627A0 (it) Procedimento e dispositivo per l'immagazzzinaggio e disimmagazzinaggio di collettame
HUP0101947A3 (en) Combination for the treatment of tumors
EP1137938A4 (en) METHODS FOR DETECTION OF HDPXU17 RECEPTOR AGONISTS AND ANTAGONISTS
FR2781118B1 (fr) Equipement d'ensileuse
HU0001888D0 (en) 5ht1 receptor agonists and either cox-2 inhibitor or nsaid for the treatment of migraine
AU2002212441A1 (en) Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain
PL337154A1 (en) Novwel compounds, substituted cycloheptenes, method of obtaining them and therapeutic agent